Mylan Company Profile (NASDAQ:MYL)

Analyst Ratings

Consensus Ratings for Mylan (NASDAQ:MYL) (?)
Ratings Breakdown: 7 Hold Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $58.86 (25.41% upside)

Analysts' Ratings History for Mylan (NASDAQ:MYL)
Show:
DateFirmActionRatingPrice TargetActions
7/12/2016Morgan StanleyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2016Goldman Sachs Group Inc.DowngradeConviction-Buy -> Buy$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Leerink SwannLower Price TargetOutperform$53.00 -> $51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/21/2016Wells Fargo & Co.Reiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016BTIG ResearchReiterated RatingBuy$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016ArgusLower Price TargetBuy$65.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016GuggenheimReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Royal Bank Of CanadaReiterated RatingHold$60.00 -> $58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Cowen and CompanyLower Price TargetMarket Perform$65.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/16/2015BMO Capital MarketsLower Price TargetMarket Perform$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/21/2015Barclays PLCInitiated CoverageEqual Weight$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/26/2015Standpoint ResearchInitiated CoverageBuy$70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015SusquehannaLower Price TargetPositive$85.00 -> $68.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Deutsche Bank AGReiterated RatingBuy$65.00 -> $66.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Sanford C. BernsteinLower Price Target$83.00 -> $60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2015B. RileyInitiated CoverageBuy$85.00 -> $71.23View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2015Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/22/2015CRT CapitalBoost Price TargetBuy$68.00 -> $87.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2014S&P Equity ResearchReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2014Bank of America Corp.Reiterated RatingBuy$68.00 -> $50.23View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2014ING GroupReiterated RatingBuy$68.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014Evercore ISIInitiated CoverageHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2014Keefe, Bruyette & WoodsReiterated RatingOutperform$60.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Mylan (NASDAQ:MYL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2016Q415$1.27$1.22$2.71 billion$2.49 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115$0.69$0.70$1.87 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214$0.73$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114$0.68$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013$0.62$0.62$1.69 billion$1.63 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/25/2012$0.77$0.83ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012$0.55$0.60ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$0.51$0.52ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/21/2012$0.50$0.53ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/26/2011$0.51$0.55ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/27/2011$0.45$0.52ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2011$0.44$0.44ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2011$0.45$0.45ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mylan (NASDAQ:MYL)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Mylan (NASDAQ:MYL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mylan (NASDAQ:MYL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014C ToddDirectorSell10,000$53.00$530,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Mylan (NASDAQ:MYL)
DateHeadline
07/27/16 09:01 PMThe Wall Street Journal: FTC give go-ahead for Mylan’s $7.2 billion purchase of Meda - Mylan NV has received U.S. Federal Trade Commission approval for its roughly $7.2 billion purchase of Swedish rival Meda, conditioned on Mylan divesting rights to two generic drugs.
07/27/16 07:58 PMFTC give go-ahead for Mylan’s $7.2 billion purchase of Meda -
07/27/16 05:42 PMFTC: Mylan (MYL) Agrees to Certain Divestitures to Clear Meda Deal
07/27/16 04:31 PM5:31 pm Mylan Labs confirms FTC clearance for proposed Meda (MDABY) acquisition -
07/27/16 04:19 PMMylan Receives U.S. FTC Clearance for Proposed Meda Acquisition - [PR Newswire] - HERTFORDSHIRE, England, and PITTSBURGH, July 27, 2016 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Hong Kong, Japan, Canada, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law (including the Takeover Rules), Dutch law, United Kingdom law, Danish law, Irish law and U.S. law. Mylan N.V. (NASDAQ, TASE: MYL) today announced that the U.S. Federal Trade Commission ("FTC") has cleared Mylan's proposed transaction to acquire Meda Aktiebolag (publ.) subject to Mylan's divestiture of certain products not significant to Mylan's earnings following the consummation of its recommended public offer to the shareholders of Meda to tender all their shares in Meda to Mylan (the "Offer").
07/26/16 05:39 PMEuropean regulator cracks down on drugs tested in India
07/26/16 05:39 PMMylan Wins PTAB Review Of Pfizer's Toviaz Patents
07/26/16 08:36 AMSiddartha_Resume (1)
07/26/16 08:36 AMGlobal Olanzapine Market 2016 - Lilly, Teva Pharmaceutical, Apotex Inc, Mylan Pharmaceuticals
07/26/16 06:47 AMWhy these traders are buying puts in Mylan -
07/25/16 05:27 PMCan Mylan Inc. (NASDAQ:MYL) Hit $71? - RealistInvestor.com
07/25/16 09:07 AM5 Incredibly Cheap Big Pharma Stocks -
07/24/16 04:53 PMAccounts Payable For Mylan Inc. (NASDAQ:MYL) Stood At $1076.2 - RealistInvestor.com
07/23/16 04:57 PMHundreds of Drugs May Be Suspended in EU After Flawed Tests
07/23/16 04:57 PMFlawed Indian studies spur EU regulator to back drug suspensions
07/22/16 05:13 PMNew Broker Ratings For Mylan Inc. (NASDAQ:MYL) - FTSE News
07/22/16 08:19 AMToday Mylan NV Stock Rises - Consumer Eagle
07/22/16 08:19 AMEarnings Focus and Crowd Sourced Sentiment Review for Mylan Inc. (NASDAQ:MYL) - TGP
07/22/16 03:11 AMWatch These 7 Huge Call Purchases In Friday Trade - Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Aug16 146 Calls Sweep: 676 @ ASK $6.20: 676 traded vs 0 OI: Earnings 8/3 $144.51 Ref Mylan NV (NASDAQ: MYL) ...Full story available on Benzinga.com
07/21/16 05:39 PMMylan Publishes Supplement to Meda Offer Document
07/21/16 08:13 AMEPS Roundup: SL Green Realty Corporation (NYSE:SLG), Mylan Inc. (NASDAQ:MYL), PowerSecure International, Inc ... - Engelwood Daily
07/20/16 06:03 PMAnalysts Tips to Monitor: Mylan N.V. (NASDAQ:MYL) , Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) - Street Updates
07/20/16 06:03 PMMylan Unveils Generic Crestor Tablets - Benzinga
07/20/16 03:09 PMMylan’s EpiPen price increases are Valeant-like in size, Shkreli-like in approach -
07/20/16 12:28 PMMylan Gets EC Clearance for Meda Purchase -
07/20/16 08:17 AMAbbott Labs beats estimates but profit falls 22%
07/20/16 08:17 AMAbbott Labs Profit Tops Views
07/19/16 05:28 PMEquity Roundup: Stock Performance Focus on Mylan Inc. (NASDAQ:MYL) - Press Telegraph
07/19/16 05:28 PMWhat's The Growth Forecast For Mylan Inc. (NASDAQ:MYL)? - RealistInvestor.com
07/19/16 01:32 PMMylan Is Poised to Break Sideways Trend -
07/19/16 09:26 AMPulmatrix and Mylan Report Positive Pharmacokinetic Bioavailability Data in Pilot Study of PUR0200 in …
07/18/16 10:40 AMMylan Inc. (NASDAQ:MYL) Quarterly Accounts Payable At $1076.2 Millions - RealistInvestor.com
07/17/16 09:37 AMMylan Inc. (NASDAQ:MYL) Broker Price Targets For The Coming Week - Fiscal Standard
07/16/16 04:57 PMMadison allergy sufferers face rising EpiPen prices
07/15/16 04:24 PMResume.DanielleDunstan.20160715
07/15/16 09:57 AMCrowd Rating and Earnings Recap for Mylan Inc. (NASDAQ:MYL) - Telanagana Press
07/15/16 09:31 AMExclusive - EU to approve Mylan's $7.2 billion bid for Swedish drugmaker: sources -
07/14/16 08:57 AMCase studies on drug development and novel targets from Glenmark Pharmaceuticals and Novartis at COPD 2016
07/14/16 08:57 AMReport Delivers Financial and Competitive Overview of U.S. Thyroid Gland Disorder Treatment Industry 2016
07/14/16 08:57 AMInvestorsObserver releases covered-call reports for Google Inc., The Blackstone Group, Yahoo!, Mylan and Sonic
07/14/16 07:10 AMTeva (TEVA) Provides 2016-2019 Outlook, Shares Gain -
07/13/16 05:43 PMConsensus Target and Stock Rating Report: Mylan Inc. (NASDAQ:MYL) - Telanagana Press
07/13/16 05:43 PMEarnings Check and Company Target Review for Mylan Inc. (NASDAQ:MYL) - Press Telegraph
07/13/16 05:43 PMMylan Inc. (NASDAQ:MYL) Updated Price Targets - FTSE News
07/13/16 08:18 AMKeyBank to close 70 First Niagara branches
07/12/16 05:37 PMCicero FD won't buy expensive EpiPens
07/12/16 05:37 PMLawyers in Provigil Antitrust Case Argue Numerosity
07/12/16 05:37 PMMylan Infringed Forest's Savella Drug Patents, Judge Rules
07/12/16 04:06 PMThese Four Drugs Were Withdrawn by the CHMP in June -
07/12/16 09:42 AMTrading Performance and Target Watch for Mylan Inc. (NASDAQ:MYL) - Press Telegraph

Social

About Mylan

Mylan logoMylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Company's generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Company's API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: MYL
  • CUSIP: 62853010
Key Metrics:
  • Previous Close: $46.93
  • 50 Day Moving Average: $44.94
  • 200 Day Moving Average: $45.87
  • P/E Ratio: 30.03
  • P/E Growth: 0.67
  • Market Cap: $23.86B
  • Beta: 1.26
  • Current Year EPS Consensus Estimate: $4.93 EPS
  • Next Year EPS Consensus Estimate: $5.92 EPS
Additional Links:
Mylan (NASDAQ:MYL) Chart for Thursday, July, 28, 2016